Company intelligence / Profile preview

Raphael Pharmaceutical Inc.

Jaffa/Tel Aviv-Jaffa, Israelraphaelpharmaceutical.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has successfully completed a proof-of-concept clinical trial demonstrating that its highly purified cannabinoid formula reduces key parameters of rheumatoid arthritis. The formulation shows anti-inflammatory potential and may slow RA progression. Additional preclinical work supports further development in inflammatory diseases and oncology supportive care.[1][2]

Therapeutic areas: OncologyPulmonologyRheumatologyInfectious Diseases
Modalities: Highly purified cannabinoids (including cannabidiol oil)
Industry: Biotech

Partnerships

Research collaborations with Israel’s leading scientific institutions; specific names not disclosed but referenced as “Israel's most renowned scientific institutions” on the company website.[1]

Beyond the preview

Go deeper on Raphael Pharmaceutical Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Raphael Pharmaceutical Inc..